

# CRUK Cancer Data Driven Detection (CD3) Programme

L. Edwards<sup>1</sup>, C. Asselborn<sup>1</sup>, C. Gordon<sup>2</sup>, A. E. Stokes<sup>2</sup>, S. Dolwani<sup>3</sup>, A. Doroszkuk<sup>2</sup>  
A. Akbari<sup>4</sup>, R. Chiovloni<sup>4</sup>, M. Garcia-Closas<sup>5</sup>, A. C. Antoniou<sup>2</sup> & the CD3 Consortium

<sup>1</sup>Health Data Research UK, UK <sup>2</sup>University of Cambridge, UK <sup>3</sup>Cardiff University, UK

<sup>4</sup>Swansea University, UK <sup>5</sup>Institute for Cancer Research, UK



**CD3**  
Cancer Data  
Driven Detection


## Background

**The (CD3) Programme:** Newly launched, 5-year, multidisciplinary and multi-institutional strategic national research programme dedicated to using data to transform our understanding of cancer risk and enable early interception of cancers.

**Aim:** Addressing gaps highlighted by the Cancer Research UK Early Detection and Diagnosis Roadmap, the programme aims to improve our understanding of who is most at risk of developing cancer and advance our ability to prevent, detect and diagnose cancers early.

## Priority Research Questions

### Research Question 01



#### Diverse data resources available:

- Equitably support cancer research
- Enhancing, adding “cancer value”
- Harnessing by scientific community

### Research Question 02



#### Multifactorial cancer risk models:

- Asymptomatic, symptomatic
- Risk-stratified prevention, early detection and diagnosis






Figure 1: Overview of the CD3 Programme. Activities will be organised in two workstreams, three research Driver Programmes, and four cross-cutting themes on PPIE, EDI, clinical practitioner involvement and ethics, regulatory and governance.

## Deliverables



**Improve cancer risk prediction & stratification** for both asymptomatic and symptomatic populations, enabling more targeted screening, diagnostic, and prevention approaches for those most likely to benefit.



**Benefit researchers** by providing a legacy of data accessibility, advanced analytics, open access repositories, and cancer risk prediction tools, and by building cancer data science capacity.



**Foster partnerships** with patients, the public and practitioners, supporting the implementation of data-driven cancer risk prediction and detection in routine healthcare.

## Data & Infrastructure

①

### Electronic health record (EHR) & administrative infrastructure:

- Build on readily accessible data to maximize the potential for cancer research

②

### UK-based and international consented cohorts:

- Use existing detailed multimodal data collected by individual studies & generate new data through new linkages
- Clean & standardise data across cohorts




Figure 2: Overview of UK wide CD3 EHR, administrative & cohort data sources

## Pathway to Clinical Impact





Figure 3: Clear pathway to clinical impact (current and future interventions).

## Pilot Project

- **Aim:** Feasibility study linking cancer service data with administrative data within SAIL Databank. Focus on 2021 Census to build robust study cohorts & providing sufficient data to investigate cancer disparities.
- **Results:** revealed sociodemographic factors influencing cancer screening participation, with single individuals, those with lower education, and those from more deprived areas being less likely to engage in screenings.

Scan QR code to read about the ADR Wales Data Insight



## Acknowledgements

The CD3 Programme is funded through a strategic programme award by Cancer Research UK, the National Institute for Health and Care Research (NIHR), Engineering and Physical Sciences Research Council (EPSRC) and the Peter Sowerby Foundation; in partnership with Health Data Research UK (HDR UK) & the Economic and Social Research Council's Administrative Data Research UK programme (ADR UK).

Scan QR code to read more about the CRUK CD3 Programme

